Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine vs Desvenlafaxine in MDD
NCT04448431Phase 4Completed
- Sponsor
- Lundbeck
- Start
- Jun 2020
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
A Phase 4 trial of vortioxetine in major depressive disorder (MDD), sponsored by Lundbeck. Started Jun 2020; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04448431.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04448431.